Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Literature
1.
Tao LH, Zhou XR, Li FC et al (2017) A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer. Cancer Immunol Immunother 66(3):309–318. doi:10.​1007/​s00262-016-1936-0 CrossRefPubMed
2.
Specht E, Kaemmerer D, Sanger J, Wirtz RM, Schulz S, Lupp A (2015) Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms. Histopathology 67(3):368–377. doi:10.​1111/​his.​12662 CrossRefPubMed
3.
Wang W, Sun J, Li F et al (2012) A frequent somatic mutation in CD274 3′-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. Hum Mutat 33(3):480–484. doi:10.​1002/​humu.​22014 CrossRefPubMed
Metadata
Title
A gene polymorphism in PD-L1 promoter region is not associated with PD-L1 expression and patients’ survival in gastric cancer
Authors
Weili Wang
Ping Liao
Yijing He
Publication date
01-10-2017
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 10/2017
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-017-2017-8

Other articles of this Issue 10/2017

Cancer Immunology, Immunotherapy 10/2017 Go to the issue

Letter to the Editors

Intralesional interleukin-2 for unresectable mucosal melanoma refractory to nivolumab

Original Article

A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma

Original Article

CD45RA−Foxp3high regulatory T cells have a negative impact on the clinical outcome of head and neck squamous cell carcinoma

Original Article

Decreased human leukocyte antigen A*02:01 frequency is associated with risk of glioma and existence of human cytomegalovirus: a case–control study in Northern China

Original Article

Macrophage-derived interleukin-1beta promotes human breast cancer cell migration and lymphatic adhesion in vitro

Review

Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits